CytomX Therapeutics (NASDAQ:CTMX) has earned an average rating of “Buy” from the thirteen research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $40.17.
A number of equities analysts have recently weighed in on CTMX shares. Citigroup started coverage on shares of CytomX Therapeutics in a research report on Friday, January 5th. They issued a “buy” rating and a $40.00 price objective for the company. Zacks Investment Research lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, February 5th. Cantor Fitzgerald set a $40.00 price objective on shares of CytomX Therapeutics and gave the company a “buy” rating in a research report on Saturday, March 17th. BidaskClub raised shares of CytomX Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 7th. Finally, Bank of America boosted their price objective on shares of CytomX Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, March 8th.
In other news, CFO Debanjan Ray sold 2,548 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $26.69, for a total value of $68,006.12. Following the completion of the sale, the chief financial officer now owns 4,741 shares of the company’s stock, valued at $126,537.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rachel Humphrey sold 23,840 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $30.00, for a total transaction of $715,200.00. Following the completion of the sale, the insider now directly owns 54,074 shares of the company’s stock, valued at approximately $1,622,220. The disclosure for this sale can be found here. Insiders have sold 103,548 shares of company stock valued at $3,101,686 in the last ninety days. 4.70% of the stock is currently owned by company insiders.
Shares of NASDAQ CTMX opened at $28.61 on Thursday. CytomX Therapeutics has a 12-month low of $13.00 and a 12-month high of $35.00. The stock has a market capitalization of $1,145.98, a price-to-earnings ratio of -24.66 and a beta of 0.91.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.45. The business had revenue of $27.07 million during the quarter, compared to analyst estimates of $10.70 million. CytomX Therapeutics had a negative net margin of 60.17% and a negative return on equity of 71.42%. equities research analysts expect that CytomX Therapeutics will post -1.44 EPS for the current fiscal year.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.